| tumor suppressor gene PAX5 is inactivated by promoter methylation in liver cancer. PAX5 contributes to suppression of hepatocarcinogenesis by inhibiting cell proliferation and inducing cell apoptosis through direct regulating p53 signaling pathway. | liver, |
| PAX5 is a novel functional tumor suppressor in gastric carcinogenesis | gastric, |
| PAX5 was found to be an epigenetically inactivated tumor suppressor that inhibited non-small-cell lung proliferation and metastasis, through down-regulating the beta-catenin pathway and up-regulating GADD45G expression. | lung, |
| function of PAX5 as a haploinsufficient tumor suppressor in BCP-ALL by a novel role of biallelic PAX5 alterations, which cooperate with impaired cell cycle control (CDKN2A/B) and sustained proliferative signaling (RAS) to drive leukemogenesis. | None |
| Pax5 contributes to lymphomagenesis by deregulating the T-cell gene-expression program. Pax5 is a potent oncogene. The T-lymphoid lineage is particularly sensitive to the oncogenic action of Pax5. | lymphoma, |
| we have demonstrated that the lymphoid leukemia-associated protein, PAX5-PML chimeric oncogenic protein, could bind to PAX5 response-element as homodimer to inhibit the transactivation of PAX5 target-genes | leukemia, |